APB-B004

APB-B004 is a bispecific monoclonal antibody currently in the discovery and preclinical development stage by APITBIO for the treatment of solid cancers. It is designed to simultaneously target CD171 (also known as L1 cell adhesion molecule or L1CAM) and a second, undisclosed target. CD171 is a transmembrane glycoprotein that is frequently overexpressed in various aggressive solid tumors, where it plays a significant role in promoting tumor cell migration, invasion, and resistance to chemotherapy. By utilizing a bispecific format, APB-B004 aims to achieve enhanced tumor specificity and therapeutic efficacy compared to conventional monoclonal antibodies by potentially engaging dual signaling pathways or facilitating targeted immune cell recruitment to the tumor microenvironment.